Seres Therapeutics Inc (MCRB) was Reiterated by H.C. Wainwright to “Buy” while Lowering the Price Target of the company shares to $ 15 from a previous price target of $50 . H.C. Wainwright advised their investors in a research report released on Aug 1, 2016.
Many Wall Street Analysts have commented on Seres Therapeutics Inc. Seres Therapeutics Inc was Downgraded by BofA/Merrill to ” Neutral” on Aug 1, 2016. H.C. Wainwright Resumed Seres Therapeutics Inc on Jul 29, 2016 to “Buy”, Price Target of the shares are set at $50.
On the company’s financial health, Seres Therapeutics Inc reported $-0.50 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on May 16, 2016. Analyst had a consensus of $-0.46. The company had revenue of $2.70 million for the quarter, compared to analysts expectations of $.83 million.
Seres Therapeutics Inc closed down -24.83 points or -69.42% at $10.94 with 3,82,89,953 shares getting traded on Friday. Post opening the session at $8.52, the shares hit an intraday low of $8.05 and an intraday high of $12.35 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Jul 29, 2016, John G. Aunins (Chief Technology Officer & EVP) sold 9,250 shares at $35.00 per share price. According to the SEC, on Jul 29, 2016, Michele Trucksis (Chief Medical Officer and EVP) sold 4,156 shares at $35.18 per share price. On Jul 28, 2016, Roger Pomerantz (President and CEO) sold 20,000 shares at $35.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Seres Therapeutics Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a range of biological drugs Ecobiotic microbiome therapeutics. It is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome in the human body. Its products include SER-109 which is designed to prevent further recurrences of Clostridium difficile infection (CDI) a debilitating infection of the colon; SER-109; SER-262 and SER-155. It’s SER-262 is a multi-strain Ecobiotic microbiome therapeutic to be used following antibiotic treatment of primary CDI to prevent an initial recurrence of CDI. The Company is developing SER-287 to treat ulcerative colitis. It is developing SER-155 which is an Ecobiotic microbiome therapeutic to treat enteric pathogens.